February 25, 2009 — In premenopausal women with early breast cancer, adjuvant therapy with the luteinizing hormone-releasing hormone agonist goserelin (Zoladex, AstraZeneca) decreases the long-term ...

Review the side-effects of Goserelin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Predictors of pathologic response and correlation with long-term outcomes in a trial of neoadjuvant concurrent paclitaxel radiation in locally advanced breast cancer (LABC). Background: Nonrandomised ...

Ovarian failure is a common toxic effect of chemotherapy, and previous studies evaluating the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function showed mixed results.

Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer Overall, patients receiving ...

Details concerning the Goserelin medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...

Two years of adjuvant endocrine therapy for premenopausal breast cancer protected against metastatic recurrence for 20 years, a new analysis of a randomized trial showed. Premenopausal women who ...

Early menopause can be prevented and fertility may be preserved in young women with early stage breast cancer, according to a study published today in The New England Journal of Medicine. A major ...

New findings from a federally funded phase III clinical trial, S0230/POEMS, indicate that adding a hormone suppressing drug called goserelin to standard chemotherapy may be an effective method of ...

Current standard adjuvant therapies for premenopausal women with early breast cancer include ovarian ablation by surgery or irradiation, chemotherapy and tamoxifen. The value of ovarian ablation in ...

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...